

- 32) Coombes JS, McNaughton LR. Effects of branched-chain amino acid supplementation on serum creatine kinase and lactate dehydrogenase after prolonged exercise. *J Sports Med Phys Fitness* 2000; 40: 240-246
- 33) 武藤 泰敏ほか. 肝硬変患者における分岐鎖アミノ酸顆粒 BCAA-G の用量反応性試験. *JJPEN*,1992; 14(3), 172-196
- 34) Harm J. Gijsman, Antonina Scarnà, Catherine J. Harmer, Sarah F.B. McTavish, John Odontiadis, Philip J. Cowen, Guy M. Goodwin. A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. *Psychopharmacology* (2002) 160:192-197
- 35) A SCARNÀ, H. J. GIJSMAN, S. F. B. McTAVISH, C. J. HARMER, P. J. COWEN and G. M. GOODWIN. Effects of a branched-chain amino acid drink in mania. *BJP* 2003, 182:210-213
- 36) 武藤達也, 小林直美, 真田進, 岡田啓, 高橋潔, 多賀谷恒明, ほか. 肝不全用経口アミノ酸製剤の比較検討～アンケート調査の分析～. *医薬ジャーナル*. 1998;34:3081-9
- 37) 小越 章平, 佐藤 博, 岡 博, 織田 敏次. 多施設共同による肝障害成分栄養剤 ED-H の臨床研究. *JJPEN*. 1987;9(3):391-406.
- 38) Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology* 2001; 40:1262-1273
- 39) Oddis CV, Rider LG, Reed AM et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. *Arthritis Rheum* 2005; 52: 2607-2615
- 40) Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology* 2004; 43: 49-54
- 41) Rider LG, Giannini EH, Brunner HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum* 2004; 50: 2281-2290
- 42) Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. *Ann Rheum Dis*. 2012;71 Suppl 2:i82-5
- 43) Zong M, Dorph C, Dastmalchi M et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. *Ann Rheum Dis*. 2014; 73(5): 913-920
- 44) Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. *Ann Neurol* 2011; 70:427-436
- 45) Alemo Munters L, Dastmalchi M, Katz A et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. *Arthritis Res Ther*. 2013;15(4): R83

- 46) Kendall FP: Testing and Function. 4 ed.. Boltimore: Williams and Wilkins; 1993
- 47) Rider LG, Koziol D, Giannini EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care Res* 2010; 62: 465-472
- 48) Miyasaka N, Hara M, Koike T et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. *Mod Rheumatol.* 2012; 22(3): 382-93
- 49) Gray S et al. Kelly's Textbook of Rheumatology Eight Edition. SAUNDERS ELSEVIER, Philadelphia, 2009, 1374-1376
- 50) Hara M, Kinoshita M, Saito E et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis. *Mod Rheumatol.* 2003 Dec; 13(4): 319-325.
- 51) Shimajima Y, Ishii W, Matsuda M et al. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study. *BMC Musculoskeletal Disorders* 2012;13:228
- 52) Gray S et al. Kelly's Textbook of Rheumatology Eight Edition. SAUNDERS ELSEVIER, Philadelphia, 2009, 875
- 53) Available from: <http://www.niehs.nih.gov/research/resources/collab/imacs/diseaseactivity/index.cfm>
- 54) Kagen LJ. History, physical examination and laboratory tests in the evaluation of myopathy. In: Wortmann RL , editor. Diseases of skeletal muscle. Philadelphia. Lipincott Williams and Wilkins; 2000. p. 255-66.
- 55) Beaufriere B, Horber FF, Schwenk WF, Marsh HM, Matthews D, Gerich JE, et al. Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. *Am J Physiol.* 1989;257:E712-21.
- 56) Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. *J Clin Invest.* 1984;73(2):412-20.
- 57) 濱田広一郎. アミノ酸飲料が運動パフォーマンスに及ぼす可能性. *臨床スポーツ医学.* 2005;22(7):823-8.
- 58) In: 香川芳子, editor. 改訂日本食品アミノ酸組成表五訂食品成分表. 女子栄養大学出版部; 2003. p. 256-75.
- 59) 日本臨床 2005 栄養学会雑誌 27 (1) : 1-10, 2005
- 60) 折笠秀樹. 臨床研究デザイン 医学研究における統計入門 . 真興交易医書出版部; 1995.
- 61) Josefson A, Romanus E, Carlsson J. A functional index in myositis. *J Rheumatol.*
- 62) Alexanderson H, Reed AM, Ytterberg SR. The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA. *J Rheumatol.* Nov;39(11):2134-41 (2012)
Aug;23(8):1380-4 (1996)

- 63) Csuka M, McCarty DJ. Simple method for measurement of lower extremity muscle strength. *Am J Med. Jan;78(1):77-81 (1985)*
- 64) Alexanderson HI, Lundberg IE. Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. *Clin Exp Rheumatol. Nov-Dec;25(6 Suppl 47):153-8 (2007)*

